BR112016007390A2 - vacina de haemophilus parasuis sorotipo tipo quatro - Google Patents

vacina de haemophilus parasuis sorotipo tipo quatro

Info

Publication number
BR112016007390A2
BR112016007390A2 BR112016007390A BR112016007390A BR112016007390A2 BR 112016007390 A2 BR112016007390 A2 BR 112016007390A2 BR 112016007390 A BR112016007390 A BR 112016007390A BR 112016007390 A BR112016007390 A BR 112016007390A BR 112016007390 A2 BR112016007390 A2 BR 112016007390A2
Authority
BR
Brazil
Prior art keywords
vaccine
haemophilus parasuis
serotype type
serotype
infection
Prior art date
Application number
BR112016007390A
Other languages
English (en)
Other versions
BR112016007390A8 (pt
Inventor
Kirubakaran Lawrence Paulraj
F Bey Russell
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of BR112016007390A2 publication Critical patent/BR112016007390A2/pt
Publication of BR112016007390A8 publication Critical patent/BR112016007390A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

resumo de patente de invenção para: “vacina de haemophilus parasuis sorotipo tipo quatro”. a presente invenção é uma vacina contra haemophilus parasuis contra o serotipo tipo 4 capaz de desencadear uma resposta imune protetora quando administrada a porcos como uma vacina morta. a presente invenção é também um método para a vacinação de porcos contra a infecção por haemophilus parasuis, serotipo tipo 4, por a) propagar clonalmente uma ou mais células que são capazes de desencadear uma resposta imune contra a infecção por haemophilus parasuis, serotipo do tipo 4, que protege o porco contra infecção por haemophilus parasuis, e b) combinar uma quantidade imunologicamente eficaz das células com um veículo veterinário aceitável em uma forma adequada para administração como uma vacina para o porco, e c) administrar como uma vacina morta. a cultura de células é de uma cepa parental patogênica
BR112016007390A 2013-10-04 2014-10-06 Vacina de haemophilus parasuis sorotipo tipo quatro BR112016007390A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361886991P 2013-10-04 2013-10-04
PCT/US2014/059330 WO2015051371A2 (en) 2013-10-04 2014-10-06 Haemophilus parasuis vaccine serovar type four

Publications (2)

Publication Number Publication Date
BR112016007390A2 true BR112016007390A2 (pt) 2017-10-10
BR112016007390A8 BR112016007390A8 (pt) 2022-09-27

Family

ID=51830630

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016007390A BR112016007390A8 (pt) 2013-10-04 2014-10-06 Vacina de haemophilus parasuis sorotipo tipo quatro

Country Status (9)

Country Link
US (1) US9504740B2 (pt)
EP (1) EP3052126A2 (pt)
JP (1) JP2016533353A (pt)
KR (1) KR20160065198A (pt)
CN (1) CN105992592A (pt)
BR (1) BR112016007390A8 (pt)
CA (1) CA2926190C (pt)
RU (1) RU2673715C2 (pt)
WO (1) WO2015051371A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9132183B2 (en) * 2007-03-09 2015-09-15 Newport Laboratories Modified live (JMSO strain) Haemophilus parasuis vaccine
CN105543120B (zh) * 2015-09-17 2020-06-19 龙岩学院 一种副猪嗜血杆菌五价灭活疫苗
CN106234299A (zh) * 2016-07-26 2016-12-21 陆川县珊罗镇振兴猪场 一种猪的饲养方法
CN111793130B (zh) * 2019-03-20 2021-09-14 华中农业大学 一株副猪嗜血杆菌CdtB杂交瘤细胞及单克隆抗体应用
CN109971685B (zh) * 2019-04-09 2022-11-29 武汉轻工大学 一种副猪嗜血杆菌感染猪腹膜间皮细胞模型的构建方法
CN113018426B (zh) * 2021-02-07 2023-06-09 河南省农业科学院畜牧兽医研究所 用于制备副猪嗜血杆菌疫苗的组合菌株、八价灭活疫苗及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404253B2 (en) * 2006-12-28 2013-03-26 Newport Laboratories, Inc. Modified live (JMSO strain) Haemophilus parasuis vaccine
CN101721696A (zh) * 2009-12-18 2010-06-09 西南民族大学 猪副嗜血杆菌血清4型、5型、13型三价油乳剂灭活疫苗
WO2011131789A1 (en) * 2010-04-23 2011-10-27 Intervet International B.V. A vaccine comprising inactivated cells of haemophilus parasuis bacteria of serotype 5
CN102908615B (zh) * 2011-08-01 2014-11-19 普莱柯生物工程股份有限公司 副猪嗜血杆菌病三价灭活疫苗及制备方法
CN102329746B (zh) * 2011-08-16 2013-01-09 武汉科前动物生物制品有限责任公司 猪链球菌、副猪嗜血杆菌病二联灭活疫苗及制备方法
CN102499982B (zh) * 2011-12-21 2013-07-17 青岛易邦生物工程有限公司 副猪嗜血杆菌三价灭活疫苗的生产方法
CN103194413B (zh) * 2013-04-11 2014-12-03 江苏省农业科学院 一株血清4型副猪嗜血杆菌疫苗株
CN103182077B (zh) * 2013-04-11 2015-05-13 江苏省农业科学院 一株血清4型副猪嗜血杆菌疫苗株的应用

Also Published As

Publication number Publication date
US9504740B2 (en) 2016-11-29
RU2673715C2 (ru) 2018-11-29
BR112016007390A8 (pt) 2022-09-27
KR20160065198A (ko) 2016-06-08
US20150098968A1 (en) 2015-04-09
JP2016533353A (ja) 2016-10-27
CA2926190A1 (en) 2015-04-09
CA2926190C (en) 2023-05-09
RU2016116988A3 (pt) 2018-05-22
WO2015051371A2 (en) 2015-04-09
CN105992592A (zh) 2016-10-05
EP3052126A2 (en) 2016-08-10
RU2016116988A (ru) 2017-11-10
WO2015051371A3 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
BR112016007390A2 (pt) vacina de haemophilus parasuis sorotipo tipo quatro
AR089797A1 (es) Vacunas contra clostridum difficile que comprenden toxinas recombinantes
MX2017009308A (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
BR112012023046A2 (pt) vacinas de vírus de febre aftosa recombinantes e seus respectivos usos
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
BR112015000161A2 (pt) composições de vetor de vírus adeno-associado modificado
BR112015027281A8 (pt) usos de uma população de nanocarreadores sintéticos que são fixados a imunossupressores e composição compreendendo a referida população de nanocarreadores
BR112018017307A2 (pt) molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
BR112015030229A2 (pt) Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
BR112015008417A8 (pt) composição imunogênica, vacina, e, uso de uma composição imunogênica
MX2017010908A (es) Vacuna bivalente contra el virus de gripe porcina.
ECSP14023048A (es) Agentes terapéuticos para administración subcutánea optimizados
CL2017000120A1 (es) Composiciones en suspensión de ciclosporina a para inyecciones subconjuntivales y perioculares
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
BR112016026651A2 (pt) evolução de vesículas semelhantes a vírus de alta titulação para aplicações de vacina
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
BR112015017903A2 (pt) vacina de subunidade de mycobacterium avium subsp. paratuberculosis única ou de múltiplos estágios
BR112015022044A2 (pt) um método de proporcionar neutroproteção ocular
BR112013001462B8 (pt) Composições

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: MERIAL, INC. (US)

B25A Requested transfer of rights approved

Owner name: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)

B25A Requested transfer of rights approved

Owner name: NEWPORT LABORATORIES, INC. (US)

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]